Insider Selling: Lexeo Therapeutics (NASDAQ:LXEO) CEO Sells 55,000 Shares of Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Richard Nolan Townsend sold 55,000 shares of the business’s stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $5.69, for a total value of $312,950.00. Following the completion of the transaction, the chief executive officer directly owned 340,106 shares in the company, valued at $1,935,203.14. This represents a 13.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Richard Nolan Townsend also recently made the following trade(s):

• On Wednesday, February 18th, Richard Nolan Townsend sold 10,173 shares of Lexeo Therapeutics stock. The stock was sold at an average price of $6.38, for a total value of $64,903.74.

Lexeo Therapeutics Trading Up 9.4%

LXEO stock traded up $0.54 during trading on Tuesday, reaching $6.31. 1,144,943 shares of the stock were exchanged, compared to its average volume of 1,065,644. The firm’s 50 day moving average is $6.55 and its 200 day moving average is $7.98. Lexeo Therapeutics, Inc. has a twelve month low of $1.75 and a twelve month high of $10.99. The firm has a market cap of $467.51 million, a P/E ratio of -2.88 and a beta of 1.99.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its quarterly earnings results on Monday, March 30th. The company reported ($0.27) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.05. As a group, analysts predict that Lexeo Therapeutics, Inc. will post -3.14 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. Chardan Capital reaffirmed a “buy” rating and set a $17.00 price target on shares of Lexeo Therapeutics in a research note on Tuesday, January 13th. HC Wainwright decreased their price objective on Lexeo Therapeutics from $13.00 to $10.00 and set a “buy” rating for the company in a report on Tuesday, January 13th. Oppenheimer reissued an “outperform” rating and set a $20.00 price objective on shares of Lexeo Therapeutics in a report on Wednesday, December 10th. Finally, Raymond James Financial started coverage on Lexeo Therapeutics in a report on Wednesday, December 17th. They set a “strong-buy” rating and a $25.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $18.88.

Institutional Trading of Lexeo Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LXEO. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Lexeo Therapeutics by 69.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,547 shares of the company’s stock valued at $35,000 after acquiring an additional 1,459 shares in the last quarter. Vanguard Personalized Indexing Management LLC grew its holdings in shares of Lexeo Therapeutics by 10.6% in the third quarter. Vanguard Personalized Indexing Management LLC now owns 16,595 shares of the company’s stock valued at $110,000 after acquiring an additional 1,595 shares in the last quarter. Bank of America Corp DE grew its holdings in shares of Lexeo Therapeutics by 6.1% in the third quarter. Bank of America Corp DE now owns 28,279 shares of the company’s stock valued at $188,000 after acquiring an additional 1,626 shares in the last quarter. California State Teachers Retirement System grew its holdings in shares of Lexeo Therapeutics by 123.7% in the fourth quarter. California State Teachers Retirement System now owns 3,884 shares of the company’s stock valued at $39,000 after acquiring an additional 2,148 shares in the last quarter. Finally, Intech Investment Management LLC grew its holdings in shares of Lexeo Therapeutics by 19.5% in the fourth quarter. Intech Investment Management LLC now owns 14,188 shares of the company’s stock valued at $141,000 after acquiring an additional 2,317 shares in the last quarter. 60.67% of the stock is owned by institutional investors.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc is a clinical?stage biotechnology company dedicated to developing novel, precision?designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next?generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.